- Myriad Genetics (NASDAQ:MYGN) has agreed to acquire genetic testing provider Counsyl for $375M, of which up to 25% can be MYGN stock. The transaction should close in calendar Q3.
- South San Francisco, CA-based Counsyl, founded in 2007, provides reproductive and cancer testing services.
- MYGN will host a conference call this morning at 7:30 am to discuss the deal.
Myriad Genetics to acquire Counsyl for $375M in cash and stock
Recommended For You
More Trending News
About MYGN Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
MYGN | - | - |
Myriad Genetics, Inc. |